Innovative Machinery Added to San Diego and Melbourne Sites Enhances Global Offerings
PHILADELPHIA–(BUSINESS WIRE)–PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced the addition of three new exceptional automated sterile fill-finish machines in its San Diego and Melbourne facilities. Purchased from Cytiva, this remarkable equipment can pivot between filling different sterile medications into vials and syringes. The addition of these machines comes after PCI’s recent acquisition of Lyophilization Services of New England, Inc. (LSNE), specialists in the manufacturing of complex injectables for biologics and small molecules, bringing even broader capabilities to PCI clients across the entire product lifecycle and allowing them to bring their life-changing therapies to market with increased speed and safety.
“The addition of this cutting-edge equipment in two key locations – San Diego and Melbourne – is part of our global strategy to increase our sterile fill-finish capabilities and help alleviate the worldwide capacity shortage for sterile drugs manufacturing and packaging,” said Tim Roberts, Chief Commercial Officer, PCI Pharma Services. “The increase in number of novel drug products in development across several therapeutic areas, combined with high demand to produce COVID-19 vaccines, has made it more and more difficult for pharmaceutical companies to partner with trusted CDMOs with expertise and capacity to meet their drug product manufacturing needs. The Cytiva technology will allow PCI to offer our clients additional sterile fill-finish capabilities to support their clinical development and manufacturing and ultimately bringing important therapies to market faster across the globe.”
PCI has invested in a Microcell Vial Filler and SA25 Aseptic Filling Workcell, in its San Diego facility to ensure the delivery of medicines from phase 1 through phase 3, supporting local and global Clinical client needs. Additionally, a Microcell Vial Filler has been placed in Melbourne to further enhance the early-stage services there, and to bring additional capacity to Australia – the world’s leading phase I environment. These advanced machines expedite the filling process with automation and remove the need for human intervention in a sterile environment. Each unit is contained in an isolator, creating increased patient safety and compliance advantage over PCI’s peers only using hand filling technology to deliver batches of medicine. The machines are already at PCI’s facilities and are expected to be fully operational in September 2022. This investment will enhance the offerings from LSNE, which includes global manufacturing capabilities in complex formulations, high potency, sterile fill-finish, and lyophilization, an important manufacturing process commonly used with injectable and biologic therapies such as vaccines and cancer treatments.
“Our Melbourne and San Diego facilities are located where a high volume of early phase clinical trials are taking place and key biopharmaceutical organizations are located. This expansion is part of our plan to better serve our clients by adding capabilities which complement our integrated offerings in clinical trial services such as packaging and S&D that create ease and simplicity in key business hubs,” said Brad Payne, Chief Operating Officer, PCI Pharma Services. “The integration of this leading-edge equipment into important global sites will create even more efficient biopharmaceutical supply chains for PCI and its clients, leveraging new technologies so we can continue bringing necessary drugs to patients faster, together with our clients.”
About PCI Pharma Services
PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. We currently have 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany and Spain) and over 4,300 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner with the shared goal of improving patients’ lives. For more information, please visit pci.com
Contacts
Ty Guzman-Touchberry, WE Communications
tgtouchberry@we-worldwide.com / +1-212-551-4877